News

Zofingen/Schlieren - Siegfried has acquired a stake of 95 percent in DiNAMIQS. The global life sciences firm is planning to bring the development and production platform for cell and gene therapy from DiNAMIQS to commercial scale. Siegfried expects to generate new growth opportunities on this basis.

Zurich - In total, 14 Swiss companies are ranked among the top 500 companies worldwide in terms of corporate research spending. In Roche, Switzerland is even represented in the top ten. In terms of total research expenditure by companies, Switzerland is ranked in fifth place.

Zurich/Lugano - The start-up platform Hoop has reported the first fully digital company foundation in Switzerland. In partnership with the IT service provider DeepCloud and the new digital bank Yapeal, this process was completed in just six hours. After a soft launch for 20 trustees, all interested parties should be able to take advantage of this service from June.

Zurich - A team from the Swiss Federal Institute of Technology in Zurich (ETH) has examined the interactions between human cells and their natural environment. The focus of this research was on influencing factors behind cell growth. The findings should now help in the development of new cancer treatments.

Zug - SHL Medical is developing an autoinjector for MoonLake Immunotherapeutics. This is intended to secure the clinical and potential commercial supply of MoonLake’s drug candidate sonelokimab, a nanobody technology for the treatment of inflammatory diseases such as psoriasis.

Zug - Aphaia Pharma has dosed the first patient in a phase 2 trial evaluating its lead candidate for prediabetes. APH-012 is expected to improve glucose tolerance in patients with this condition.

Zurich - Helbling helps companies improve the usability of industrial tools and business applications. The result is user interfaces of devices, machines and systems that can be operated more intuitively. This increases employees’ efficiency and motivation.

Zurich - Researchers from the Swiss Federal Institute of Technology in Zurich and University Hospital Zurich have a new method at their disposal to predict the best possible treatment approach for all multiple myeloma patients. This form of blood cancer remains incurable and often returns despite treatment.

Schaffhausen - The driverless electric bus used on STL Line 13 has officially taken to the roads of Schaffhausen. This is Switzerland’s first dual mode technology bus. The project is the brainchild of the Swiss Transit Lab mobility initiative.